| Tanuja A Mainkar, MD | |
|
4320 Seminary Rd, Alexandria, VA 22304-1535 | |
| (703) 504-3789 | |
| (703) 504-3556 |
| Full Name | Tanuja A Mainkar |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Location | 4320 Seminary Rd, Alexandria, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386643849 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 0101230927 (Virginia) | Primary |
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952461816 PECOS PAC ID: 3779495858 Enrollment ID: O20040105000308 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced the first use of the company's renal denervation catheter and generator system, as part of a feasibility study of the new technology. The technology was developed as a treatment for resistant hypertension (high blood pressure that is not well controlled by drug therapy).
Today, more than 2.5 million U.S. grandparents are raising their grandchildren due to the opioid crisis and other social issues
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
Cancer stem cells are defined by three abilities: differentiation, self-renewal and their ability to seed a tumor. These stem cells resist chemotherapy and many researchers posit their role in relapse. A University of Colorado Cancer Center study recently published in the journal Stem Cells, shows that melanoma cells with these abilities are marked by the enzyme ALDH, and imagines new therapies to target high-ALDH cells, potentially weeding the body of these most dangerous cancer creators.
› Verified 6 days ago
| Entity Name | North American Partners In Anesthesia (virginia), Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922031442 PECOS PAC ID: 9931192739 Enrollment ID: O20040407000294 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced the first use of the company's renal denervation catheter and generator system, as part of a feasibility study of the new technology. The technology was developed as a treatment for resistant hypertension (high blood pressure that is not well controlled by drug therapy).
Today, more than 2.5 million U.S. grandparents are raising their grandchildren due to the opioid crisis and other social issues
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
Cancer stem cells are defined by three abilities: differentiation, self-renewal and their ability to seed a tumor. These stem cells resist chemotherapy and many researchers posit their role in relapse. A University of Colorado Cancer Center study recently published in the journal Stem Cells, shows that melanoma cells with these abilities are marked by the enzyme ALDH, and imagines new therapies to target high-ALDH cells, potentially weeding the body of these most dangerous cancer creators.
› Verified 6 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1578638425 PECOS PAC ID: 3779495858 Enrollment ID: O20040805001280 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced the first use of the company's renal denervation catheter and generator system, as part of a feasibility study of the new technology. The technology was developed as a treatment for resistant hypertension (high blood pressure that is not well controlled by drug therapy).
Today, more than 2.5 million U.S. grandparents are raising their grandchildren due to the opioid crisis and other social issues
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
Cancer stem cells are defined by three abilities: differentiation, self-renewal and their ability to seed a tumor. These stem cells resist chemotherapy and many researchers posit their role in relapse. A University of Colorado Cancer Center study recently published in the journal Stem Cells, shows that melanoma cells with these abilities are marked by the enzyme ALDH, and imagines new therapies to target high-ALDH cells, potentially weeding the body of these most dangerous cancer creators.
› Verified 6 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1073678637 PECOS PAC ID: 3779495858 Enrollment ID: O20100729000796 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced the first use of the company's renal denervation catheter and generator system, as part of a feasibility study of the new technology. The technology was developed as a treatment for resistant hypertension (high blood pressure that is not well controlled by drug therapy).
Today, more than 2.5 million U.S. grandparents are raising their grandchildren due to the opioid crisis and other social issues
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
Cancer stem cells are defined by three abilities: differentiation, self-renewal and their ability to seed a tumor. These stem cells resist chemotherapy and many researchers posit their role in relapse. A University of Colorado Cancer Center study recently published in the journal Stem Cells, shows that melanoma cells with these abilities are marked by the enzyme ALDH, and imagines new therapies to target high-ALDH cells, potentially weeding the body of these most dangerous cancer creators.
› Verified 6 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1366781700 PECOS PAC ID: 3779495858 Enrollment ID: O20130507000207 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced the first use of the company's renal denervation catheter and generator system, as part of a feasibility study of the new technology. The technology was developed as a treatment for resistant hypertension (high blood pressure that is not well controlled by drug therapy).
Today, more than 2.5 million U.S. grandparents are raising their grandchildren due to the opioid crisis and other social issues
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
Cancer stem cells are defined by three abilities: differentiation, self-renewal and their ability to seed a tumor. These stem cells resist chemotherapy and many researchers posit their role in relapse. A University of Colorado Cancer Center study recently published in the journal Stem Cells, shows that melanoma cells with these abilities are marked by the enzyme ALDH, and imagines new therapies to target high-ALDH cells, potentially weeding the body of these most dangerous cancer creators.
› Verified 6 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1497023188 PECOS PAC ID: 3779495858 Enrollment ID: O20131029000108 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced the first use of the company's renal denervation catheter and generator system, as part of a feasibility study of the new technology. The technology was developed as a treatment for resistant hypertension (high blood pressure that is not well controlled by drug therapy).
Today, more than 2.5 million U.S. grandparents are raising their grandchildren due to the opioid crisis and other social issues
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
Cancer stem cells are defined by three abilities: differentiation, self-renewal and their ability to seed a tumor. These stem cells resist chemotherapy and many researchers posit their role in relapse. A University of Colorado Cancer Center study recently published in the journal Stem Cells, shows that melanoma cells with these abilities are marked by the enzyme ALDH, and imagines new therapies to target high-ALDH cells, potentially weeding the body of these most dangerous cancer creators.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tanuja A Mainkar, MD 68 S. Service Rd., Ste 350, Melville, NY 11747-2358 Ph: (516) 945-3107 | Tanuja A Mainkar, MD 4320 Seminary Rd, Alexandria, VA 22304-1535 Ph: (703) 504-3789 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced the first use of the company's renal denervation catheter and generator system, as part of a feasibility study of the new technology. The technology was developed as a treatment for resistant hypertension (high blood pressure that is not well controlled by drug therapy).
Today, more than 2.5 million U.S. grandparents are raising their grandchildren due to the opioid crisis and other social issues
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the award of four grants totaling $977,917 under the Qualifying Therapeutic Discovery Project program. The grant funding will support Halozyme's ongoing Ultrafast Insulin, PEGPH20, HTI-501, and drug delivery development programs that are directed at addressing unmet medical needs across a broad range of therapeutic areas such as diabetes, cancer and immunology.
Cancer stem cells are defined by three abilities: differentiation, self-renewal and their ability to seed a tumor. These stem cells resist chemotherapy and many researchers posit their role in relapse. A University of Colorado Cancer Center study recently published in the journal Stem Cells, shows that melanoma cells with these abilities are marked by the enzyme ALDH, and imagines new therapies to target high-ALDH cells, potentially weeding the body of these most dangerous cancer creators.
› Verified 6 days ago
Dr. Talha Siddiqui, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 6164 Fuller Ct, Alexandria, VA 22310 Phone: 571-257-9580 | |
Reed S Underwood, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-504-3789 Fax: 703-504-3556 | |
Dr. Julie A Miller, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2501 Parkers Ln, Alexandria, VA 22306 Phone: 703-295-9360 Fax: 703-295-9369 | |
Carl Anderson Smith, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 200 Duke St, Alexandria, VA 22314 Phone: 703-299-0125 | |
Dr. Rebecca L Freese, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2501 Parkers Ln, Alexandria, VA 22306 Phone: 703-664-7049 Fax: 703-295-9369 | |
Mrs. Cheryl V Lynch, CRNA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 4320 Seminary Rd, Inova Alexandria Hospital, Alexandria, VA 22304 Phone: 703-504-3789 Fax: 703-504-3556 | |
Aristides John Michos, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4320 Seminary Rd, Alexandria, VA 22304 Phone: 703-504-3789 |